CY1124378T1 - Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w - Google Patents
Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-wInfo
- Publication number
- CY1124378T1 CY1124378T1 CY20211100400T CY211100400T CY1124378T1 CY 1124378 T1 CY1124378 T1 CY 1124378T1 CY 20211100400 T CY20211100400 T CY 20211100400T CY 211100400 T CY211100400 T CY 211100400T CY 1124378 T1 CY1124378 T1 CY 1124378T1
- Authority
- CY
- Cyprus
- Prior art keywords
- herv
- diseases associated
- envelope protein
- compounds
- remyelination
- Prior art date
Links
- 102100021696 Syncytin-1 Human genes 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title 1
- 108010037253 syncytin Proteins 0.000 title 1
- 101710091045 Envelope protein Proteins 0.000 abstract 2
- 101710188315 Protein X Proteins 0.000 abstract 2
- 210000000653 nervous system Anatomy 0.000 abstract 2
- 101000820777 Homo sapiens Syncytin-1 Proteins 0.000 abstract 1
- 241000005822 Human endogenous retrovirus W Species 0.000 abstract 1
- 241000896769 Multiple sclerosis associated retrovirus Species 0.000 abstract 1
- 102000006386 Myelin Proteins Human genes 0.000 abstract 1
- 108010083674 Myelin Proteins Proteins 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000005012 myelin Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση ασχολείται με καινοτόμες ενώσεις και συνθέσεις για πρόληψη και/ή αγωγή ενός νεο-ανακαλυφθέντος επιβλαβούς μηχανισμού, ο οποίος αποκλείει την ικανότητα επιδιόρθωσης ενδογενούς μυελίνης του νευρικού συστήματος (NS) ενηλίκων σε παθήσεις που συσχετίζονται με την έκφρασης της πρωτεΐνης φακέλου (ENV) HERV-W, ειδικότερα του υπο-τύπου MSRV αυτής.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708779P | 2012-10-02 | 2012-10-02 | |
| US201261746792P | 2012-12-28 | 2012-12-28 | |
| PCT/EP2013/070452 WO2014053489A1 (en) | 2012-10-02 | 2013-10-01 | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein |
| EP13770926.7A EP2904009B1 (en) | 2012-10-02 | 2013-10-01 | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124378T1 true CY1124378T1 (el) | 2022-07-22 |
Family
ID=49274655
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100169T CY1121237T1 (el) | 2012-10-02 | 2019-02-07 | Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w |
| CY20211100400T CY1124378T1 (el) | 2012-10-02 | 2021-05-11 | Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100169T CY1121237T1 (el) | 2012-10-02 | 2019-02-07 | Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9840550B2 (el) |
| EP (2) | EP2904009B1 (el) |
| JP (2) | JP6379331B2 (el) |
| KR (1) | KR102098033B1 (el) |
| CN (2) | CN104684927B (el) |
| AU (2) | AU2013326552B2 (el) |
| BR (1) | BR112015007150A8 (el) |
| CA (1) | CA2882781C (el) |
| CY (2) | CY1121237T1 (el) |
| DK (2) | DK3447070T3 (el) |
| EA (2) | EA028245B1 (el) |
| EC (1) | ECSP15014925A (el) |
| ES (2) | ES2710748T3 (el) |
| HK (1) | HK1221399A1 (el) |
| HR (2) | HRP20190274T1 (el) |
| HU (2) | HUE043419T2 (el) |
| IL (3) | IL237474A0 (el) |
| IN (1) | IN2015DN02397A (el) |
| LT (2) | LT3447070T (el) |
| MX (2) | MX366846B (el) |
| MY (1) | MY172209A (el) |
| PL (2) | PL3447070T3 (el) |
| PT (2) | PT2904009T (el) |
| RS (2) | RS61794B1 (el) |
| RU (1) | RU2636355C2 (el) |
| SA (1) | SA515360207B1 (el) |
| SG (1) | SG11201501274VA (el) |
| SI (2) | SI3447070T1 (el) |
| UA (1) | UA119032C2 (el) |
| WO (1) | WO2014053489A1 (el) |
| ZA (1) | ZA201501491B (el) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2949342A1 (en) * | 2014-05-28 | 2015-12-02 | Geneuro SA | Antiretroviral drug targeting human endogenous retrovirus |
| EP3351265A1 (en) * | 2017-01-20 | 2018-07-25 | Geneuro SA | Anti-herv-k envelope antibody and uses thereof |
| WO2018159787A1 (ja) | 2017-03-01 | 2018-09-07 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
| US20210405011A1 (en) * | 2018-09-01 | 2021-12-30 | National University Corporation Hokkaido University | Pharmaceutical for preventing and/or treating stress load-related disease |
| US20220332799A1 (en) * | 2019-09-04 | 2022-10-20 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Herv inhibitors for use in treating tauopathies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753098B1 (fr) * | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
| AU5829201A (en) * | 2000-03-21 | 2001-10-03 | Ms Research A/S | An infective endogenous retrovirus and its association with demyelinating diseases and other diseases |
| CA2433877C (en) * | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| FR2865403B1 (fr) * | 2004-01-23 | 2009-06-12 | Biomerieux Sa | Composition pour le traitement d'une pathologie associee a la msrv/herv-w |
| WO2006102536A2 (en) * | 2005-03-23 | 2006-09-28 | University Of Southern California | Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth |
| US8410115B2 (en) * | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| ES2599227T3 (es) * | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Neuroprotección en enfermedades desmielinizantes |
| EP2219673A1 (en) * | 2007-11-12 | 2010-08-25 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
| MX2010014319A (es) | 2008-07-08 | 2011-05-19 | Geneuro Sa | Uso terapeutico de ligando especifico en enfermedades asociadas con msrv. |
| EP2355660A4 (en) * | 2008-10-13 | 2012-05-02 | Biovista Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
| WO2010148323A2 (en) * | 2009-06-18 | 2010-12-23 | Whittemore Peterson Institute For Neuro-Immune Disease | Diagnosis and treatment of diseases or disorders associated with xenotropic murine leukemia virus |
| RS54551B1 (en) * | 2010-02-12 | 2016-06-30 | Biogen Ma Inc. | NEUROPROTECTION IN DEMYELINING DISEASES |
-
2013
- 2013-01-10 UA UAA201504292A patent/UA119032C2/uk unknown
- 2013-10-01 IN IN2397DEN2015 patent/IN2015DN02397A/en unknown
- 2013-10-01 EA EA201590678A patent/EA028245B1/ru unknown
- 2013-10-01 SI SI201331879T patent/SI3447070T1/sl unknown
- 2013-10-01 DK DK18198309.9T patent/DK3447070T3/da active
- 2013-10-01 PT PT13770926T patent/PT2904009T/pt unknown
- 2013-10-01 AU AU2013326552A patent/AU2013326552B2/en active Active
- 2013-10-01 LT LTEP18198309.9T patent/LT3447070T/lt unknown
- 2013-10-01 PT PT181983099T patent/PT3447070T/pt unknown
- 2013-10-01 MX MX2015003572A patent/MX366846B/es active IP Right Grant
- 2013-10-01 MY MYPI2015700643A patent/MY172209A/en unknown
- 2013-10-01 RS RS20210555A patent/RS61794B1/sr unknown
- 2013-10-01 JP JP2015533633A patent/JP6379331B2/ja active Active
- 2013-10-01 KR KR1020157011152A patent/KR102098033B1/ko active IP Right Grant
- 2013-10-01 BR BR112015007150A patent/BR112015007150A8/pt not_active Application Discontinuation
- 2013-10-01 RS RS20190185A patent/RS58320B1/sr unknown
- 2013-10-01 SI SI201331348T patent/SI2904009T1/sl unknown
- 2013-10-01 EP EP13770926.7A patent/EP2904009B1/en active Active
- 2013-10-01 PL PL18198309T patent/PL3447070T3/pl unknown
- 2013-10-01 WO PCT/EP2013/070452 patent/WO2014053489A1/en active Application Filing
- 2013-10-01 EA EA201791525A patent/EA037253B1/ru unknown
- 2013-10-01 ES ES13770926T patent/ES2710748T3/es active Active
- 2013-10-01 CA CA2882781A patent/CA2882781C/en active Active
- 2013-10-01 HU HUE13770926A patent/HUE043419T2/hu unknown
- 2013-10-01 ES ES18198309T patent/ES2878248T3/es active Active
- 2013-10-01 US US14/429,199 patent/US9840550B2/en active Active
- 2013-10-01 EP EP18198309.9A patent/EP3447070B9/en active Active
- 2013-10-01 HU HUE18198309A patent/HUE054051T2/hu unknown
- 2013-10-01 CN CN201380051713.4A patent/CN104684927B/zh active Active
- 2013-10-01 DK DK13770926.7T patent/DK2904009T3/en active
- 2013-10-01 PL PL13770926T patent/PL2904009T3/pl unknown
- 2013-10-01 SG SG11201501274VA patent/SG11201501274VA/en unknown
- 2013-10-01 CN CN201610152679.5A patent/CN105709224B/zh active Active
- 2013-10-01 RU RU2015116149A patent/RU2636355C2/ru active
- 2013-10-01 LT LTEP13770926.7T patent/LT2904009T/lt unknown
-
2015
- 2015-02-26 IL IL237474A patent/IL237474A0/en unknown
- 2015-03-04 ZA ZA2015/01491A patent/ZA201501491B/en unknown
- 2015-03-19 MX MX2019008916A patent/MX2019008916A/es unknown
- 2015-03-30 SA SA515360207A patent/SA515360207B1/ar unknown
- 2015-04-17 EC ECIEPI201514925A patent/ECSP15014925A/es unknown
-
2016
- 2016-08-01 HK HK16109172.3A patent/HK1221399A1/zh unknown
-
2017
- 2017-11-07 JP JP2017214696A patent/JP6538138B2/ja active Active
- 2017-11-14 US US15/812,745 patent/US10752675B2/en active Active
-
2018
- 2018-08-17 AU AU2018217328A patent/AU2018217328B2/en active Active
-
2019
- 2019-01-21 IL IL264382A patent/IL264382B/en active IP Right Grant
- 2019-02-07 CY CY20191100169T patent/CY1121237T1/el unknown
- 2019-02-11 HR HRP20190274TT patent/HRP20190274T1/hr unknown
-
2020
- 2020-04-19 IL IL274047A patent/IL274047B/en active IP Right Grant
-
2021
- 2021-05-11 CY CY20211100400T patent/CY1124378T1/el unknown
- 2021-05-14 HR HRP20210779TT patent/HRP20210779T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124378T1 (el) | Ενωσεις για αγωγη του αποκλεισμου επαναμυελινωσης σε παθησεις που συσχετιζονται με την εκφραση της πρωτεϊνης φακελου herv-w | |
| CY1122631T1 (el) | Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων | |
| CY1124663T1 (el) | Αντιιικα παραγωγα ν4-υδροξυκυτιδινης | |
| CY1122144T1 (el) | Αιθερες αρυλιου και χρησεις εξ αυτων | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1124617T1 (el) | Ενωσεις βενζολιου υποκατεστημενες με αρυλιο ή ετεροαρυλιο | |
| CY1121542T1 (el) | Μορια αντισωματων σε pd-1 και χρηση αυτων | |
| CY1121299T1 (el) | Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr | |
| CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
| CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
| CY1121360T1 (el) | Αναστολεις dna-pk | |
| CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
| CY1120556T1 (el) | Δικυκλικα ετεροκυκλα ως αναστολεις fgfr | |
| CY1121076T1 (el) | Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες | |
| CY1119245T1 (el) | Φαρμακευτικη συνθεση καρβετοκινης | |
| CY1124869T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια της αναιμιας | |
| EA201791310A1 (ru) | Химерные антигенные рецепторы к bcma | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| EA201590504A1 (ru) | Индолкарбоксамидные производные и их применение | |
| PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
| UA111098C2 (uk) | Проліки адреномедуліну на основі поліетиленгліколю і їх застосування | |
| EA201590272A1 (ru) | Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб | |
| CY1123596T1 (el) | Θεραπεια της κοκκιδιωσης με ενδομυϊκες συνθεσεις τριαζινης | |
| EA201791174A1 (ru) | Антимикотическое соединение | |
| CY1120276T1 (el) | Απομονωμενη στερεη μορφη μονοϋδροχλωρικη αναμορελινης με χαμηλη γραμμομοριακη αναλογια χλωριου:αναμορελινης και χαμηλη περιεκτικοτητασε καταλοιπα οργανικου διαλυτη |